Maravai LifeSciences (MRVI) News
Filter MRVI News Items
MRVI News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
MRVI News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest MRVI News From Around the Web
Below are the latest news stories about MARAVAI LIFESCIENCES HOLDINGS INC that investors may wish to consider to help them evaluate MRVI as an investment opportunity.
Maravai LifeSciences Announces Preliminary Unaudited 2024 RevenueAnnounces Earnings Release DateSAN DIEGO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that based on preliminary year-end results and subject to year-end closing adjustments, the Company expects to report total 2024 revenue near the mid-point of the previously announced guidance range of $255.0 million and $265.0 million. The Company al |
Maravai Lifesciences initiated with a Neutral at GuggenheimGuggenheim initiated coverage of Maravai Lifesciences (MRVI) with a Neutral rating as the firm expands its bioprocessing tools coverage. Maravai is a leading pure-play in mRNA capping and viral clearance assessment and while the current valuation likely limits downside, the firm’s Neutral view is based on its call that there are “more attractive categories within the bioprocessing subsegment.” Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. T |
Exploring December 2024's Undervalued Small Caps With Insider Action In USOver the last 7 days, the United States market has experienced a 4.0% drop, yet it remains up by 24% over the past year with anticipated earnings growth of 15% per annum in the coming years. In this dynamic environment, identifying promising small-cap stocks with insider activity can offer investors unique opportunities to capitalize on potential market inefficiencies. |
Maravai LifeSciences Appoints R. Andrew Eckert as Chairman of the Board of DirectorsCarl Hull to Retire as Executive ChairmanSAN DIEGO, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (“Maravai” or the “Company”) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that Carl Hull will retire from his position as Executive Chairman of the Board and that the Board of Directors has unanimously elected R. Andrew Eckert to succeed him as Chairman of the Board, effective December 5, 2024. Carl H |
Exploring ACNB And 2 More Undervalued Small Caps With Insider Buying In USOver the last 7 days, the United States market has dropped by 1.2%, yet it has risen by an impressive 30% over the past year, with earnings forecasted to grow by 15% annually. In this dynamic environment, identifying stocks that are perceived as undervalued and have insider buying can be a promising strategy for investors looking to capitalize on potential growth opportunities. |
Maravai LifeSciences Announces November 2024 Investor Conference ScheduleSAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conferences in November. On November 19, 2024, at 8:30 a.m. PST/ 11:30 a.m. EST, Kevin Herde, Chief Financial Officer, and Drew Burch, President, Nucleic Acid Production, will participate in a fireside chat at the Stifel Healthcare Conference in New York, NY. On |
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Just Reported Earnings, And Analysts Cut Their Target PriceAs you might know, Maravai LifeSciences Holdings, Inc. ( NASDAQ:MRVI ) last week released its latest quarterly, and... |
Maravai Lifesciences price target lowered to $9 from $10 at BairdBaird analyst Catherine Schulte lowered the firm’s price target on Maravai Lifesciences (MRVI) to $9 from $10 and keeps an Outperform rating on the shares. The firm said they reported 3Q results below expectations, with both segments light versus the firm’s model. In NAP, the company noted soft research/discovery demand, a lack of larger drop-in orders, and a few GMP program timing delays into 2025. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial n |
Q3 2024 Maravai LifeSciences Holdings Inc Earnings CallQ3 2024 Maravai LifeSciences Holdings Inc Earnings Call |
Top Midday DeclinersTop Midday Decliners |